Skip to Content

'
Bela B. Toth, MS, DDS

Present Title & Affiliation

Primary Appointment

Professor, Department of Head and Neck Surgery, Division of Surgery, Section of Oncologic Dentistry, The University of Texas M. D. Anderson Cancer, Houston, TX

Clinical Interests

Chemoprevention of Oral Premalignant Lesions

Latent Effects of Cancer Therapy on Oral Structures

Mucositis

Non-Neoplastic Lesions

Oral Premalignant Lesions

Osteonecrosis of Jaws due to Bisphosphonate Therapy

Osteoradionecrosis

Polymicrobial Oral Infection in Patients undergoing Chemotherapy or Bone Marrow Transplantation

Xerostomia

Office Address

The University of Texas M. D. Anderson Cancer Center
Department of Head and Neck Surgery
1515 Holcombe Boulevard
Unit Number: 1445
Houston, TX 77030-4009
Room Number: FCT 10.6032
Fax: 713-794-4662

Education & Training

Degree-Granting Education

1971 Loma Linda University, Loma Linda, CA, DDS, Doctorate of Dental Surgery
1967 Loma Linda University, Loma Linda, CA, BS, Medical Technology
1966 Loma Linda University, Loma Linda, CA, MS, Microbiology. Thesis: Host and Prophage Modifications of Ultraviolet Induction in Salmonella Potsdam
1963 La Sierra College, La Sierra, CA, BS, Biology

Postgraduate Training

1974 Certificate in Oral Pathology (36 months), The University of Texas Dental Branch and UT M. D. Anderson Hospital and Tumor Institute, Houston, TX

Board Certifications

1976 American Academy of Oral Pathology
1976 American Board of Oral Pathology

Experience/Service

Academic Appointments

Associate Professor, The University of Texas Dental Branch, Houston, TX, 1/1985

Honors and Awards

1988 Literary Award, Texas Section of the International College of Dentists
1974 American Cancer Society Fellowship
1971 Educational Opportunities Grant

Selected Publications

Peer-Reviewed Original Research Articles
1. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, Cui J, Adamus A, Gagel RF, Hortobagyi GN. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 23(6):826-36, 6/2008. PMID: 18558816.
2. Hoff AO, Toth BB, Altundag K, Johnson MM, Warneke CL, Hu M, Nooka A, Sayegh G, Guarneri V, Desrouleaux K, Cui J, Adamus A, Gagel RF, Hortobagyi GN. The Frequency and Risk Factors Associated with Osteonecrosis of the Jaw in Cancer Patients Treated with Intravenous Bisphosphonates. J Bone Miner Res. e-Pub 2/2008. PMID: 18435574.
3. Chambers MS, Fleming TJ, Toth BB, Lemon JC, Craven TE, Bouwsma OJ, Garden AS, Espeland MA, Keene HJ, Martin JW, Sipos T. Erratum to "Clinical evaluation of the intraoral fluoride releasing system in radiation-induced xerostomic subjects. Part 2: Phase I study". Oral Oncol 43(1):98-105, 1/2007. PMID: 18027401.
4. Ruggiero S, Gralow J, Marx R, Toth BB. Practical Guidelines for the Prevention, Diagnosis, and Treatment of Osteonecrosis of the Jaws in Patients with Cancer. J Oncology Practice(2):7-14, 2006.
5. Chambers MS, Keene HJ, Toth BB, Lemon JC, Gallagher SC, Martin CG, Martin JW. Mutans streptococci in xerostomic cancer patients after pilocarpine therapy: a pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 99(2):180-4, 2/2005. PMID: 15660089.

Last updated: 9/1/2009